• Investors may be wondering whether Johnson & Johnson at around US$230 per share still offers value after a strong run, or whether they might be late to the story.
• The stock last closed at US$230.18, with returns of 0.1% over 7 days, 1.2% over 30 days, 11.0% year to date, 54.0% over 1 year, 62.8% over 3 years and 60.1% over 5 years. These figures raise fair questions about how much potential future upside or downside is already reflected in the price.
• Recent headlines around Johnson & Johnson have focused on its portfolio, capital allocation choices and ongoing legal matters, which all factor into how investors weigh future cash flows and risk. This context helps explain why the share price has been closely watched, along with any updates that could influence sentiment toward the stock's long-term prospects.
• Simply Wall St currently gives Johnson & Johnson a valuation score of 4 out of 6. The sections ahead will compare different valuation methods and also outline a more complete way to think about what this stock might be worth.

Approach 1: Johnson & Johnson Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model estimates what a stock could be worth by projecting the company’s future cash flows and discounting them back to today’s value. It is essentially asking what those future dollars are worth in your hands right now.

For Johnson & Johnson, the model used is a 2 Stage Free Cash Flow to Equity approach, based on cash flow projections. The latest twelve month Free Cash Flow is about $17.0b. Analyst inputs are provided out to 2030, with projected Free Cash Flow for that year of $35.9b, and further estimates out to 2035 are extrapolated by Simply Wall St rather than based directly on analyst forecasts.

When all those projected cash flows are discounted back to today and summed, the DCF model points to an estimated intrinsic value of about $374.05 per share. Compared with the recent share price of around $230, this indicates the stock is roughly 38.5% below that intrinsic value estimate. This suggests a potentially meaningful valuation gap if the assumptions hold.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Johnson & Johnson is undervalued by 38.5%. Track this in your watchlist or portfolio, or discover 46 more high quality undervalued stocks.

Approach 2: Johnson & Johnson Price vs Earnings

For a profitable company, the P/E ratio is a straightforward way to link what you pay for the stock to the earnings it currently generates. It lets you see how many dollars investors are paying for each dollar of earnings, which is a simple anchor for comparing valuation across similar businesses.

What counts as a “normal” or “fair” P/E depends on how the market views a company’s growth prospects and risk. Higher expected growth or lower perceived risk often goes with a higher P/E, while lower growth or higher risk tends to be associated with a lower P/E.

Johnson & Johnson trades on a P/E of 26.34x. This is very close to the peer average of 26.66x, and above the broader Pharmaceuticals industry average of 15.45x. Simply Wall St’s Fair Ratio for Johnson & Johnson is 28.55x, which is its proprietary view of what the P/E could be given factors such as earnings growth, profit margins, industry, market cap and risk profile. This Fair Ratio can be more tailored than simple peer or industry comparisons because it adjusts for those company specific drivers. Since the Fair Ratio of 28.55x is moderately above the current 26.34x, Johnson & Johnson screens as somewhat inexpensive on this measure.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your Johnson & Johnson Narrative

Earlier it was mentioned that there is an even better way to understand valuation, so Narratives on Simply Wall St give you a clear story that links your view on Johnson & Johnson, your forecast for its future revenue, earnings and margins, and your resulting fair value. It then compares that fair value to the current price to help you decide whether the stock looks attractive or stretched.

On the Community page, Narratives are easy to use and update automatically when new earnings, news or forecasts arrive. This means you always see a live view of how the story and valuation line up for you.

For Johnson & Johnson, one investor Narrative on the platform currently points to a fair value of about US$133.00 per share, while another points to about US$265.00 per share. This shows how different assumptions about growth, margins, legal risks or MedTech opportunities can lead to very different stories about the same stock.

For Johnson & Johnson, however, we’ll make it really easy for you with previews of two leading Johnson & Johnson Narratives:

Fair value in this bullish narrative: US$252.96 per share

Implied discount to this fair value relative to the current price: about 9.0% below the narrative fair value

Revenue growth assumption used: 6.54% per year

• Analysts in this narrative see Johnson & Johnson building on its drug portfolio and MedTech pipeline, with products like ICOTYDE, TECVAYLI combinations and cardiovascular acquisitions feeding into higher future revenue and earnings.
• The view assumes profit margins edge higher and earnings reach about US$26.9b by 2029, with the stock trading on a P/E of 27.8x, which is above the current Pharmaceuticals industry level quoted in the narrative.
• Key risks flagged include loss of exclusivity for STELARA, tariff related cost pressure, ongoing talc litigation and execution challenges in areas like orthopedics and integration of acquisitions.

Fair value in this more cautious narrative: US$173.55 per share

Implied premium to this fair value relative to the current price: about 32.7% above the narrative fair value

Revenue growth assumption used: 6.3% per year

• This narrative leans on a well filled late stage pipeline and the Kenvue spin off, but assumes a fair value that is lower than the current price, even after allowing for revenue growth and a 20% profit margin over time.
• The author assumes around US$8b of annual buybacks, a future P/E of 22.2x and steady capital returns, while still treating patent expiries, drug success rates and litigation costs as meaningful constraints on valuation.
• Main risks highlighted include unresolved lawsuits around talc and opioids, patent expirations on major drugs and uncertainty around how much of the pipeline will ultimately convert into successful commercial products.

To see how these different stories are built and decide which one lines up more closely with your own view, it is worth reading the full narratives alongside the data in your Simply Wall St account, then adjusting the assumptions to match your expectations.

Do you think there's more to the story for Johnson & Johnson? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.